Sarepta Therapeutics (SRPT) Misses Q4 EPS by 237c
Tweet
Share
E-mail
Get Alerts SRPT Hot Sheet
Join SI Premium – FREE
Sarepta Therapeutics (NASDAQ: SRPT) reported Q4 EPS of ($3.58), $2.37 worse than the analyst estimate of ($1.21). Revenue for the quarter came in at $442.9 million versus the consensus estimate of $379.71 million.
For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- 8x8 reports data breach via third-party Salesforce integration
- Tutor Perini prices $400M in senior notes to refinance debt
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
